BioLife Q2 2026 Earnings: Revenue Rises 21% as Operating Profit Turns Positive

BioLife Solutions (Nasdaq: BLFS) reported Q2 2026 revenue of $28.5 million, up 21% from $23.4 million, while diluted GAAP EPS from continuing operations was $0.91 versus a loss of $0.32 a year earlier. The operating business returned to profitability, with adjusted EBITDA reaching $7.4 million and 26% of revenue. However, a $42.4 million noncash tax benefit accounted for most of the reported $45.1 million GAAP net income.

Core financial results

Revenue also increased 4% from Q1 2026, while gross profit grew by approximately 20% year over year. Gross margin nevertheless declined by one percentage point on both a GAAP and adjusted basis.

Operating results improved at both the reported and adjusted levels. The comparison benefited from the absence of the $15.5 million in-process research and development expense recorded in Q2 2025, but adjusted operating income also turned positive as revenue growth outpaced a modest decline in adjusted operating expenses.

Amounts reflect continuing operations unless otherwise noted. BioLife classified the divested evo business as discontinued operations for all presented periods.

Biopreservation media remains the operating anchor

Management said quarterly execution was led by BioLife’s biopreservation media franchise, although the company did not provide product-level revenue. The media products were being used in approximately 250 ongoing commercially sponsored U.S. clinical trials, representing more than 70% market share. That total included more than 30 Phase III trials, or nearly 80% of the cited late-stage trial market.

As of June 30, 2026, BioLife’s biopreservation media was embedded in 18 commercial cell and gene therapies. The company expects eight additional product approvals, geographic expansions, earlier treatment-line uses, or new indications over the following 12 months. Its CellSeal vials and human platelet lysate products were used in more than 35 clinical trials and four approved therapies.

Operating improvement is clearer than headline net income

Total operating expenses fell to $16.6 million from $31.4 million, largely because Q2 2025 included the $15.5 million IPR&D charge. On an adjusted basis, operating expenses decreased more modestly to $15.4 million from $15.8 million. General and administrative expense declined to $10.7 million, while research and development expense increased to $3.0 million from $2.0 million.

The resulting improvement was not solely an accounting comparison: adjusted operating income rose to $3.1 million from a $0.3 million loss, and adjusted EBITDA margin expanded to 26% from 24%. At the same time, GAAP and adjusted gross margins each declined by one percentage point, showing that stronger operating leverage came primarily below the gross-profit line.

A noncash tax benefit drove most of GAAP net income

BioLife recorded $2.8 million of pretax income but reported $45.1 million of GAAP net income from continuing operations. The difference came from a $42.4 million noncash income tax benefit related to the release of a valuation allowance, which represented approximately 94% of reported net income.

The company said the tax item added $0.87 to net income per share. Adjusted net income, which removes the tax benefit and other specified items, was $4.2 million, making it more representative of the quarter’s operating performance than the GAAP bottom line.

Cash flow and balance sheet

Cash, cash equivalents, and marketable securities totaled $113.1 million at June 30, 2026, down from $120.2 million at the end of 2025. Working capital increased to $121.3 million from $113.6 million, while current liabilities declined to $13.9 million from $23.0 million.

For the first six months of 2026, operating cash flow was $5.9 million, compared with $9.1 million in the prior-year period. Investing cash outflow decreased to $3.4 million from $66.7 million, while financing cash outflow increased to $11.5 million from $5.9 million. These cash-flow figures are year-to-date and consolidated across continuing and discontinued operations, rather than Q2-only figures.

Pending Repligen acquisition changes the forward focus

On July 21, 2026, BioLife entered into a definitive agreement to be acquired by Repligen for an enterprise value of approximately $1.5 billion. BioLife shareholders are set to receive $11.25 in cash and 0.1442 Repligen shares for each BioLife share.

The transaction is expected to close in Q4 2026, subject to BioLife shareholder approval, regulatory clearance, and customary closing conditions. If completed, BioLife will cease to be publicly traded. The company did not hold a quarterly conference call because of the pending transaction.

Recent insider transactions

The provided six-month insider summary reports 835,133 shares purchased across 13 transactions and 102,218 shares sold across eight transactions, producing net purchases of 732,915 shares. It also reports total insider ownership of approximately 1.16 million shares; these aggregate share figures should be distinguished from the dollar values shown for individual reported transactions below.

The latest ten reported entries consist of eight sales and two stock awards. The data alone does not establish the reasons for the transactions.

Risks investors need to watch

• Transaction completion: The Repligen acquisition still requires shareholder and regulatory approvals and remains subject to other closing conditions.
• Gross-margin pressure: GAAP and adjusted gross margins each declined by one percentage point despite 21% revenue growth. Continued pressure could limit further operating leverage.
• Cash conversion: Six-month operating cash flow declined to $5.9 million from $9.1 million, while the large quarterly GAAP profit was mostly attributable to a noncash tax benefit.
• Cell and gene therapy milestones: BioLife’s commercial opportunity depends partly on therapy approvals, geographic expansion, new indications, and progression of clinical programs using its products.

Summary

BioLife’s Q2 2026 results showed meaningful operating progress: revenue rose 21%, adjusted operating income turned positive, and adjusted EBITDA margin expanded to 26%. The $45.1 million GAAP profit overstated recurring earnings because it included a $42.4 million noncash tax benefit, while the one-point decline in gross margin and lower year-to-date operating cash flow remain important operating indicators. With the Repligen acquisition pending, closing approvals and the performance of BioLife’s biopreservation media franchise are now the main issues to monitor.